Indivior PLC Ordinary Shares (INDV)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
INDV
Indivior PLC Ordinary Shares
$35.43
+5.10%
HEALTHCARE · Cap: $4.45B
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.60
+0.97%
HEALTHCARE · Cap: $49.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 349181% more annual revenue ($4.51T vs $1.29B). INDV leads profitability with a 19.5% profit margin vs 4.3%. INDV trades at a lower P/E of 19.3x. INDV earns a higher WallStSmart Score of 62/100 (C+).
INDV
Buy62
out of 100
Grade: C+
TAK
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 46.1%
Earnings expanding 82.0% YoY
Conservative balance sheet, low leverage
19.2% revenue growth
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
Negative free cash flow — burning cash
Distress zone — elevated risk
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
4.3% margin — thin
Operating margin of 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : INDV
The strongest argument for INDV centers on Operating Margin, EPS Growth, Debt/Equity. Profitability is solid with margins at 19.5% and operating margin at 46.1%. Revenue growth of 19.2% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : INDV
The primary concerns for INDV are Free Cash Flow, Altman Z-Score.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
INDV profiles as a growth stock while TAK is a value play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.17 — expect wider price swings.
INDV is growing revenue faster at 19.2% — sustainability is the question.
INDV generates stronger free cash flow (-29M), providing more financial flexibility.
Bottom Line
INDV scores higher overall (62/100 vs 57/100), backed by strong 19.5% margins and 19.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?